Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...
Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, ...
It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...
Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater ...
The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...
Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1 billion, the Wall Street Journal reported on ...
Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis ...
An approval of Lilly's pill, along with its current strength in the weight loss market, could equal revenue growth well into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback